Fact CheckerSign in

NCT06122415Recruiting

The Swedish BioFINDER - Memory Clinic Study

Source: ClinicalTrials.gov · Last updated 6 Apr 2026

Brief summary (registry, in English)

The diagnosis of diseases causing memory difficulties or dementia is often challenging. Without the use of advanced methods such as cerebrospinal fluid tests, approximately 25-30% do not receive a correct diagnosis today. However, the investigators have recently developed new blood biomarkers with high diagnostic accuracy, and the investigators now want to investigate whether they can eventually replace cerebrospinal fluid tests. This is because blood tests are much more cost-effective and significantly easier for patients compared to cerebrospinal fluid tests. In this study, 1200 patients undergoing clinical evaluations at the Memory Clinic, Skåne University Hospital in Malmö, are included for blood and cerebrospinal fluid sample collection. The blood samples are sent for analysis using the new blood biomarkers. Subsequently, the results are compared with those from the clinical analysis of cerebrospinal fluid to determine how well they perform in routine clinical practice as an alternative to cerebrospinal fluid tests and whether the blood test improves patient care. This comparison is carried out by the attending physician in three steps: 1. Assessment without access to the results of either the blood test or cerebrospinal fluid test. 2. Assessment with access to only the results of the blood test. 3. Assessment with access to the results of both the blood test and cerebrospinal fluid test. Aim 1) To prospectively validate plasma Alzheimer's disease (AD) biomarkers for diagnosis of patients with cognitive symptoms who are evaluated in a specialist memory clinic. Aim 2) Determine whether blood AD biomarkers improve patient management in specialist memory clinic settings.

Status (registry)
Recruiting
Study type
Observational
Enrollment
1200 (estimated)
First submitted
2 Nov 2023
Start date
1 Dec 2022
Primary completion date
31 Dec 2026
Lead sponsor
Skane University Hospital
NCT number
NCT06122415

What you commit to

  • Study type: Observational
  • Planned participants: 1200
  • From 1 Dec 2022 to the primary completion date, 31 Dec 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other

  • Not undergoing CSF or blood sampling as part of clinical practice.
  • Not undergoing cognitive testing as part of clinical practice.

Who the study is looking for

  • Under investigation for cognitive symptoms at the Memory clinic.
  • Cerebrospinal fluid and blood sampling is planned to be done as part of clinical practice even if the patient is not taking part of this study.

Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Skåne University Hospital
Coordinator of this site? Confirm its status
MalmöSwedenRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.